A5079367748- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatitis C virus research
- Liver Diseases and Immunity
- Hepatitis B Virus Studies
- Systemic Lupus Erythematosus Research
- Hepatitis Viruses Studies and Epidemiology
- Organ Transplantation Techniques and Outcomes
- Trace Elements in Health
- Drug-Induced Hepatotoxicity and Protection
- Hormonal Regulation and Hypertension
- Pancreatitis Pathology and Treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Heavy Metal Exposure and Toxicity
- Drug Transport and Resistance Mechanisms
- SARS-CoV-2 and COVID-19 Research
- Alcohol Consumption and Health Effects
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastrointestinal Bleeding Diagnosis and Treatment
- Renal Diseases and Glomerulopathies
- Pharmacological Effects of Natural Compounds
- Selenium in Biological Systems
- Lipid metabolism and disorders
- COVID-19 Clinical Research Studies
- Diabetes and associated disorders
Medical University of Vienna
2016-2025
Vienna General Hospital
2023-2024
Pomeranian Medical University
2022
Austrian Society of Dermatology and Venereology
2015-2016
MODUL University Vienna
2016
Yale University
2015
University of Padua
2015
Medizinische Hochschule Hannover
2013
Royal College of Physicians
2013
Columbia University
2013
Sustained virologic response (SVR) to interferon (IFN)-free therapies ameliorates portal hypertension (PH); however, it remains unclear whether a decrease in hepatic venous pressure gradient (HVPG) after cure of hepatitis C translates into clinical benefit. We assessed the impact pretreatment HVPG, changes and posttreatment HVPG on development decompensation patients with PH who achieved SVR IFN-free therapy. Moreover, we evaluated transient elastography (TE) von Willebrand factor platelet...
•Progression of portal hypertension severity (reflected by HVPG) occurs mostly across compensated ACLD stages.•Systemic inflammation CRP and IL-6 levels) substantially increases only decompensated ACLD.•IL-6 levels are independent predictors first decompensation in death/liver transplantation ACLD. Background & AimsDistinct prognostic stages advanced chronic liver disease (ACLD) defined (PH) the presence/absence clinical complications. We characterised degree dysfunction, PH, systemic...
Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality in patients with advanced chronic liver disease (ACLD) caused by hepatitis C who have achieved sustained virologic response (SVR). We developed risk stratification algorithms for de novo HCC development after SVR validated them an independent cohort.We evaluated the occurrence derivation cohort 527 pre-treatment ACLD to interferon-free therapy, whom alpha-fetoprotein (AFP) non-invasive surrogates portal hypertension...
A few case reports of autoimmune hepatitis-like liver injury have been reported after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We evaluated clinical features, treatment response and outcomes following SARS-CoV-2 vaccination in a large series.We collected data from cases 18 countries. The type was assessed with the R-value. study population categorized according to features immune-mediated hepatitis (positive autoantibodies elevated immunoglobulin G levels)...
Wilson disease (WD) is an inherited disorder of hepatic copper metabolism with considerable variation in clinical presentations, the most common ones being liver and neuropsychiatric disturbances. This study investigated presentation relation to mutations a large cohort patients WD. A total 1,357 (702 children, 655 adults; 1,172 index patients, 185 siblings, all Leipzig score ≥4, male/female: 679/678) were studied. The age symptoms at used as key phenotypic markers. Index clinically...
Systemic inflammation promotes the development of clinical events in patients with advanced chronic liver disease (ACLD). We assessed whether (1) non-selective beta blocker (NSBB) treatment initiation impacts biomarkers systemic and (2) these changes predict complications mortality.Biomarkers inflammation, that is, white blood cell count (WBC), C reactive protein (CRP), interleukin-6 (IL-6) procalcitonin (PCT) were determined at sequential hepatic venous pressure gradient (HVPG) measurements...
Abstract Background and Aims Cholestasis is associated with disease severity worse outcome in COVID‐19. Cases of secondary sclerosing cholangitis (SSC) after severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection have been described. Approach Results Hospitalized patients COVID‐19 between 03/2020 07/2021 were included. Patients stratified as having (i) no chronic liver (CLD), (ii) non‐advanced CLD (non‐ACLD), or (iii) advanced (ACLD). non–COVID‐19 pneumonia matched to a...
Bulevirtide (BLV) blocks the uptake of hepatitis D virus (HDV) into hepatocytes via sodium/bile acid cotransporter NTCP. BLV was conditionally approved by EMA but real-life data on efficacy are limited.Patients were treated with monotherapy. Patients who did not achieve further decreases in HDV-RNA after 24 weeks offered PEG-IFN as an add-on therapy a response-guided manner.Twenty-three patients (m: 10, f: 13; mean age: 47.9 years, cirrhosis: 16; median ALT: 71 IU/ml; HDV-RNA: 2.1 × 105...
Baveno VII proposed liver stiffness measurement (LSM)/platelet count (PLT)-based criteria ('ruled out,' LSM ≤15 kPa plus PLT ≥150 G/L; 'ruled in': ≥25 kPa) for clinically significant portal hypertension (CSPH) in compensated advanced chronic disease (cACLD). However, a substantial proportion of patients remains 'unclassified.'Patients with evidence cACLD (LSM ≥10 undergoing hepatic venous pressure gradient (HVPG) at the Vienna General Hospital 2004 to 2021 (derivation [2004-2016], n = 221;...
Background and AimsNon-invasive tests (NIT) for assessing the probability of clinically significant portal hypertension (CSPH) including ANTICIPATE±NASH models based on liver stiffness measurement (LSM), platelet count (PLT)±body mass index (BMI), von Willebrand factor antigen (VWF) to PLT ratio (VITRO) have fundamentally changed management compensated advanced chronic disease (cACLD). However, their prognostic utility has not been compared head-to-head against hepatic venous pressure...
Summary Background Aetiological therapy improves liver function and may enable hepatic recompensation in decompensated cirrhosis. Aims We explored the potential for patients with primary biliary cholangitis (PBC) – considering a biochemical response to ursodeoxycholic acid (UDCA) according Paris‐II criteria as surrogate successful aetiological treatment. Methods Patients PBC were retrospectively included at time of first decompensation. Recompensation was defined (i) resolution ascites...
Summary Background and Aims The prognostic performance of von Willebrand factor (VWF) may vary across clinical stages advanced chronic liver disease (ACLD). Therefore, we investigated the evolution VWF other biomarkers throughout full ACLD spectrum evaluated their stage‐specific utility. Methods We retrospectively included Viennese patients with available information on hepatic venous pressure gradient (HVPG), C‐reactive protein (CRP)/VWF levels outcomes. were defined according to D'Amico et...
Risk stratification after cure from hepatitis C virus (HCV) infection remains a clinical challenge. We investigated the predictive value of noninvasive surrogates portal hypertension (liver stiffness measurement [LSM] by vibration-controlled transient elastography and von Willebrand factor/platelet count ratio [VITRO]) for development hepatic decompensation hepatocellular carcinoma in patients with pretreatment advanced chronic liver disease (ACLD) who achieved HCV cure.
Wilson disease (WD) is an autosomal recessive disorder of hepatic copper excretion. About sixty per cent patients present with liver disease. WD considered a fatal if undiagnosed and/or untreated but recent data indicate that penetrance may not be 100%.All underwent biopsy as part the diagnostic workup. Genetic testing for ATP7B was performed by Sanger sequencing.We report on large family multiple affected siblings. The first patient (male, 31 years) orthotopic transplantation (OLT) because...
Background & AimsNonselective beta blockers (NSBBs) exert beneficial effects beyond lowering hepatic venous pressure gradient (HVPG), which may be particularly relevant in patients with decompensated cirrhosis (DC), whom bacterial translocation and bacterial-induced systemic inflammation drive the development of complications such as acute-on-chronic liver failure (ACLF). We evaluated whether NSBB-related changes von Willebrand factor (VWF) serve a biomarker for these effects.MethodsIn this...
Carvedilol induces stronger decreases in hepatic venous pressure gradient (HVPG) than conventional nonselective β-blockers (ie, propranolol). Limited data exist on the efficacy of carvedilol secondary prophylaxis variceal bleeding.Patients undergoing paired HVPG measurements for guiding with either or propranolol were included this retrospective analysis. All patients also underwent band ligation. Changes and systemic hemodynamics compared between 2 groups. Long-term follow-up rebleeding,...